^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Nailike (olverembatinib) (Bcr-abl inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Promising Third-Generation TKI Olverembatinib in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed/Refractory Disease
Published date:
11/02/2023
Excerpt:
Among the 23 pts with T315I mutation, the MRD flow negativity rate in pts with T315I single mutation was significantly higher than those with additional mutations (p=0.008), and the CMR rate tended to be better (p=0.089). Meanwhile, pts with T315I single mutation showed significant improvements in PFS and OS...This study further confirmed the efficacy of olverembatinib-based therapy in Chinese adults BCR::ABL1+ ALL pts with T315I mutation or R/R disease, especially in those with T315I single mutation.
DOI:
https://doi.org/10.1182/blood-2023-188733
Source:
Title:
EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE
Published date:
05/11/2023
Excerpt:
By Jan. 15, 2023, the median follow-up time was 6 months (range, 1-10), and PFS and OS rates were 51.5% and64.5%....The novel third-generation TKI Olverembatinib is effective and safe in Chinese adult Ph/BCR-ABL1+ ALL with molecular or hematological R/R disease, especially in pts with T315I mutation.